- Home
- EBS vs YMAB Comparison
EBS vs YMAB Comparison
Compare EBS & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- YMAB
- Stock Information
- Founded
- EBS 1998
- YMAB 2015
- Country
- EBS United States
- YMAB United States
- Employees
- EBS N/A
- YMAB N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- YMAB Health Care
- Exchange
- EBS Nasdaq
- YMAB Nasdaq
- Market Cap
- EBS 518.0M
- YMAB 482.4M
- IPO Year
- EBS 2006
- YMAB 2018
- Fundamental
- Price
- EBS $10.20
- YMAB $6.19
- Analyst Decision
- EBS Strong Buy
- YMAB Strong Buy
- Analyst Count
- EBS 3
- YMAB 10
- Target Price
- EBS $14.33
- YMAB $21.10
- AVG Volume (30 Days)
- EBS 1.1M
- YMAB 417.3K
- Earning Date
- EBS 03-04-2025
- YMAB 02-27-2025
- Dividend Yield
- EBS N/A
- YMAB N/A
- EPS Growth
- EBS N/A
- YMAB N/A
- EPS
- EBS N/A
- YMAB N/A
- Revenue
- EBS $1,125,500,000.00
- YMAB $84,553,000.00
- Revenue This Year
- EBS $6.26
- YMAB $6.09
- Revenue Next Year
- EBS $2.42
- YMAB $19.62
- P/E Ratio
- EBS N/A
- YMAB N/A
- Revenue Growth
- EBS 2.05
- YMAB N/A
- 52 Week Low
- EBS $1.42
- YMAB $6.01
- 52 Week High
- EBS $15.10
- YMAB $20.90
- Technical
- Relative Strength Index (RSI)
- EBS 60.60
- YMAB 19.68
- Support Level
- EBS $9.20
- YMAB $6.05
- Resistance Level
- EBS $10.63
- YMAB $6.81
- Average True Range (ATR)
- EBS 0.67
- YMAB 0.49
- MACD
- EBS 0.05
- YMAB -0.02
- Stochastic Oscillator
- EBS 81.86
- YMAB 6.90
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.